Delivery Order SPE2DR25D1106-SPE2DR26FJA8H
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,438.70 to AmerisourceBergen Drug Corp for the supply of Prevymis 480 mg tablets (quantity 7) with a completion date of October 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the company's role as a critical pharmaceutical supplier to the federal government. The order will be fulfilled from AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $4,719.34 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Prevymis 480 mg tablets (quantity: 7 units). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by September 26, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a $4,973.46 delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Prevymis 480 mg tablets (seven-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance scheduled for completion by December 31, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $14,158.02 to AmerisourceBergen Drug Corp for the supply of Prevymis 480 mg tablets (7-count units) on October 20, 2025, with an ultimate completion date of November 10, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract for pharmaceutical procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $4,719.34 to AmerisourceBergen Drug Corp for Prevymis 480 mg tablets (7-count units) with an ultimate completion date of August 25, 2025. This is a firm fixed price, non-set-aside contract that represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Prevymis 480 mg tablets in a quantity of seven units, with a total ceiling value of $4,719.34. This firm fixed-price delivery order is scheduled for completion by October 2, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Prevymis 480 mg tablets in a quantity of seven units. This is a firm fixed-price delivery order with a ceiling value of $9,946.92 and an ultimate completion date of December 16, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Prevymis 480 mg tablets (quantity: 7 units) under a firm fixed-price contract with a ceiling value of $4,973.46. The order was competitively awarded without set-aside designation and is scheduled for completion by December 23, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location and is responsible for delivering this...
- The Defense Logistics Agency (DLA) awarded a $4,973.46 delivery order to AmerisourceBergen Drug Corp for the supply of Prevymis 480 mg tablets (7-count units) under a firm fixed-price contract. The award, issued on December 11, 2025, with completion targeted for January 5, 2026, represents a competitive procurement with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Prevymis 480 mg tablets in a quantity of 7 units, with a contract ceiling value of $4,973.46. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion by December 24, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DR25D1106Indefinite Delivery Contract
- SPE2DR25D1106-SPE2DR26FJA8HDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,946.92 to AmerisourceBergen Drug Corp for the supply of Prevymis 480 mg tablets (7-count units) on November 24, 2025. This firm fixed-price contract, which is not set-aside for small business or other designated groups, is scheduled for completion by December 16, 2025, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a routine pharmaceutical procurement under the company's existing Defense Logistics Agency contract vehicle. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal military and veteran healthcare systems, supplying a comprehensive range of medications and medical supplies. The contract vehicle supports the Defense Health Agency and other government healthcare systems globally, positioning the company as a primary source for specialty pharmaceuticals and medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.9k | 11/23/25 |